Mylan, Biocon Launch Insulin Glargine Biosimilar in the United Kingdom

Mylan and Biocon jointly announced earlier this month that their biosimilar insulin glargine, sold as Semglee and referencing Lantus, has launched in the United Kingdom. Semglee is approved in the European Union as a once-daily 100 units/mL dose, long-ac https://www.centerforbiosimilars.com/news/mylan-biocon-launch-insulin-glargine-biosimilar-in-the-united-kingdom